Rigel Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs to treat blood disorders, cancer, and rare immune diseases. The company is headquartered in South San Francisco, California.
| Revenue (TTM) | $288.21M |
| Gross Profit (TTM) | $225.05M |
| EBITDA | $79.57M |
| Operating Margin | 21.10% |
| Return on Equity | 109.20% |
| Return on Assets | 12.30% |
| Revenue/Share (TTM) | $15.60 |
| Book Value | $23.64 |
| Price-to-Book | 1.98 |
| Price-to-Sales (TTM) | 2.57 |
| EV/Revenue | 2.836 |
| EV/EBITDA | 8.35 |
| Quarterly Earnings Growth (YoY) | -55.50% |
| Quarterly Revenue Growth (YoY) | 16.50% |
| Shares Outstanding | $18.68M |
| Float | $14.96M |
| % Insiders | 3.35% |
| % Institutions | 91.57% |
Volatility is currently expanding
Rigel Pharmaceuticals NASDAQ: RIGL reported record quarterly product sales in the third quarter of 2026, helped by the launch of breast cancer treatment VEPPANU, while net income declined as spending on research and commercialization increased.
Rigel Pharmaceuticals, Inc. (RIGL) Q3 2026 Earnings Call Transcript
Third quarter 2026 total revenues of $80.9 million, including net product sales of $72.3 million and contract revenues from collaborations of $8.6 million, and net income of $13.2 million VEPPANU™ (vepdegestrant) became commercially available in mid-August and generated $6.6 million in initial net product sales for the third quarter The Phase 1b study of R289, Rigel's dual IRAK1/4 inhibitor, in patients with lower-risk MDS is ongoing and Rigel expects to select the recommended Phase 2 dose by the end of 2026 Oral presentation at the ASH Annual Meeting in December will feature updated data from the ongoing Phase 1b study of R289 in patients with lower-risk MDS Updated 2026 Outlook: Total revenues of approximately $290 to $295 million, which includes net product sales, excluding VEPPANU, of $255 to $260 million and contract revenues from collaborations of approximately $35 million Conference call and webcast scheduled today at 4:30 p.m. Eastern Time SOUTH SAN FRANCISCO, Calif.
Oral presentation to feature updated data from the dose escalation and dose expansion phases of the ongoing Phase 1b study evaluating R289, Rigel's dual IRAK1/4 inhibitor, in patients with relapsed or refractory lower-risk MDS Three poster presentations will highlight data for TAVALISSE ® (fostamatinib disodium hexahydrate) in patients with chronic ITP and wAIHA SOUTH SAN FRANCISCO, Calif., Nov. 4, 2026 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced that data from the ongoing Phase 1b clinical study of R2891, a potent and selective inhibitor of interleukin receptor-associated kinases 1 and 4 (IRAK1/4), in patients with lower-risk myelodysplastic syndrome (MDS) who are relapsed or refractory (R/R) to prior therapies will be presented in an oral session at the 68th American Society of Hematology (ASH) Annual Meeting and Exposition on Saturday, December 12, 2026.
SOUTH SAN FRANCISCO, Calif., Oct. 29, 2026 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it will report its third quarter 2026 financial results after market close on Thursday, November 5, 2026.
Rigel Pharmaceuticals is evolving into a multi-product oncology platform, leveraging Big Pharma castoffs to drive growth beyond its ITP legacy. VEPPANU's U.S. launch targets a $1B ESR1-mutated breast cancer market, with early metrics excluded from current guidance and valuation multiples. RIGL trades at a 25–39% discount to sector medians on forward P/E and EV/Sales, while base business demonstrates robust double-digit sales growth and high gross margins.
Pooled ARROW and TAPISTRY analysis demonstrated a 53% overall response rate in patients with RET fusion-positive solid tumors Additional analyses highlight first-line clinical outcomes and patient-reported quality of life in RET fusion-positive NSCLC and efficacy and safety in RET fusion-positive thyroid cancer SOUTH SAN FRANCISCO, Calif., Oct. 19, 2026 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced analysis of the pooled efficacy and safety data from two clinical trials of GAVRETO® (pralsetinib), ARROW (NCT03037385) and TAPISTRY (NCT04589845), in patients with rearranged during transfection (RET) fusion-positive solid tumors will be presented in a rapid oral session at the European Society For Medical Oncology (ESMO) Congress 2026 on Sunday, October 25, 2026.
SOUTH SAN FRANCISCO, Calif., Oct. 2, 2026 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. ("Rigel") (Nasdaq: RIGL) today announced that it has granted awards pursuant to the Rigel Pharmaceuticals, Inc. Inducement Plan, approved by the Compensation Committee of Rigel's Board of Directors and granted as an inducement material to employees entering into employment with Rigel, in accordance with NASDAQ Listing Rule 5635(c)(4).
SOUTH SAN FRANCISCO, Calif., Sept. 2, 2026 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced that Dean Schorno, the company's chief financial officer, will participate in the following investor conferences in September: Citi's 2026 Biopharma Back to School Conference in New York, NY Rigel will participate in one-on-one meetings on Wednesday, September 9.
VEPPANU is the first and only FDA-approved PROTAC and has the potential to become an important new treatment option for adult patients with 2L+ ER+/HER2-, ESR1-mutated mBC SOUTH SAN FRANCISCO, Calif., Aug. 11, 2026 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced VEPPANUTM (vepdegestrant) is now available by prescription in the United States for the treatment of adults with estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2-), estrogen receptor 1 (ESR1)-mutated advanced or metastatic breast cancer (mBC), as detected by a U.S. Food and Drug Administration (FDA)-authorized test, with disease progression following at least one line of endocrine therapy.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on RIGL and any ticker you trade — then tracks every position and per-strategy win rate.
